Suppressive effects of 4-acetylaminophenylacetic acid (Actarit (cas 18699-02-0)) on experimental autoimmune encephalomyelitis in rats

Add time:09/26/2019    Source:sciencedirect.com

To elucidate the efficacy of 4-acetylaminophenylacetic acid (actarit), an anti-rheumatic drug, on neuroinflammatory diseases such as multiple sclerosis, the effects of actarit on both actively induced and adoptively transferred experimental autoimmune encephalomyelitis (EAE) were studied. Daily intraperitoneal administration of actarit during the effector phase of active EAE and transferred EAE suppressed the clinical manifestation and pathological findings of EAE at doses of 300 mg/kg or higher. The percentages of CD4 and CD25 positive cells in the infiltrating cells in the CNS were reduced by this treatment. Semi-quantitative cytokine analysis revealed that the mRNA expression of TNF-α and INF-γ in spinal cords and spleens of actarit treated active EAE rats was significantly reduced compared with vehicle treated EAE rats. The mRNA expression of IL-10 on day 17 in spleens of actarit-treated EAE rats was significantly upregulated. Actarit is potentially useful for the treatment of neuroimmunological disorders, such as multiple sclerosis.

We also recommend Trading Suppliers and Manufacturers of Actarit (cas 18699-02-0). Pls Click Website Link as below: cas 18699-02-0 suppliers

Prev:Pharmaceutical NanotechnologyInjectable Actarit (cas 18699-02-0)-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis
Next:Short communicationSuppressive effect of Actarit (cas 18699-02-0) on IgA production in mice: Activation of Cd4+ suppressor T-cells in Peyer's patches)